Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer [RNA-seq]
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer
PubMed Full text in PMC Similar studies
The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer [HiC]
PubMed Full text in PMC Similar studies SRA Run Selector
Genome-wide chromatin interactions identify characteristic promoter-distal loops
HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance
PubMed Full text in PMC Similar studies Analyze with GEO2R
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
PubMed Similar studies Analyze with GEO2R
Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance
Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance [RNA-Seq]
Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance [Hi-C]
Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer [RNA-seq]
Breast Cell Lines: Experimental vs. Mixed Reference
Therapeutic modulation of nemo-like kinase in primary and acquired endocrine-resistant breast cancer
Acquired resistance to lapatinib
Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response
PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet
HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes
RNAseq of parental and neratinib resistant 5637 and OVCAR8 cells with or withour neratinib treatment
Temporal dynamic reorganization of 3D chromatin in hormone-induced breast cancer and endocrine resistance [T47D]
Temporal dynamic reorganization of 3D chromatin in hormone-induced breast cancer and endocrine resistance
Deregulation of the three-dimensional epigenome in endocrine resistant breast cancer
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine resistant breast cancer
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on